In the early 1920s, physicians still regarded type 1 diabetes as a death sentence. Patients suffered from relentless hyperglycemia, leading to weight loss, blindness, and kidney failure. Hospital wards were filled with people whose only hope was a strict diet that could barely prolong life. It was against this bleak backdrop that a young Canadian surgeon named Frederick Banting began to question whether the pancreas held a secret cure.
Banting’s hypothesis centered on the pancreas, an organ that had long been suspected of regulating blood sugar. Earlier researchers, including Paul Langerhans, had identified tiny clusters now called the islets of Langerhans. Banting proposed that these islands secreted a substance capable of lowering glucose levels, and that removing the surrounding digestive enzymes might allow it to be extracted. This idea was daring because no one had successfully isolated such a hormone before.
To test his theory, Banting recruited a medical student named Charles Best. In the summer of 1921 they began a series of grueling experiments on dogs whose pancreases were surgically altered. After ligating the pancreatic ducts and waiting several weeks, they harvested the tissue and produced a crude extract that, when injected, dramatically reduced blood sugar in diabetic dogs. The duo christened the active component insulin, borrowing a term coined by earlier physiologists to describe its “island” origin.
The breakthrough attracted the attention of Professor J.J.R. Macleod at the University of Toronto, who provided laboratory space and critical guidance on experimental design. Macleod’s colleague, biochemist James Collip, later refined Banting and Best’s crude preparation into a purer form suitable for human use. In January 1922 the first patient—18‑year‑old Leonard Thompson—received an injection of this purified insulin. Within hours his blood sugar fell to normal levels, and his symptoms receded dramatically, marking the world’s first successful treatment of diabetes.
The success sparked a worldwide rush to produce insulin on a larger scale. However, early preparations sometimes caused hypoglycemia if dosed too aggressively, underscoring the need for precise dosing and monitoring. Researchers soon discovered that insulin is a polypeptide hormone, composed of two chains linked by disulfide bonds, which explained its rapid action on cells throughout the body. By the mid‑1920s, pharmaceutical companies in Canada and the United States were mass‑producing insulin, turning a once‑fatal disease into a chronic condition that could be managed with daily injections.
In 1923 Banting and Macleod shared the Nobel Prize in Physiology or Medicine for their discovery. The award sparked controversy because Best, who had been instrumental in the animal work, was omitted; Banting later shared his prize money with him as a gesture of gratitude. Over the following decades, advances such as recombinant DNA technology in the 1970s allowed scientists to produce human insulin without relying on animal pancreases, further improving safety and supply.
Today, more than a century after that modest Toronto lab experiment, diabetes remains a global health challenge, but the legacy of Banting, Best, and their collaborators endures. Modern therapies—long‑acting analogues, continuous glucose monitors, and even artificial pancreas systems—trace their lineage back to the original insulin extract. The story reminds us that curiosity, perseverance, and collaboration can turn a desperate battle into a lasting victory for humanity.